BGG492 as an adjunctive treatment in patients with partial-onset seizures: A 12-week, randomized, double-blind, placebo-controlled, phase II dose-titration study with an open-label extension-Reference-Cited by-同舟云学术

BGG492 as an adjunctive treatment in patients with partial-onset seizures: A 12-week, randomized, double-blind, placebo-controlled, phase II dose-titration study with an open-label extension

Published:2017-05-13 Issue:7 Volume:58 Page:1217-1226
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Elger Christian E.¹,Hong Seung Bong²,Brandt Christian³^ORCID,Mancione Linda⁴,Han Jackie⁴,Strohmaier Christine⁵

Affiliation:

1. Department of Epileptology; University of Bonn; Bonn Germany

2. Department of Neurology; Samsung Medical Center; Samsung Advanced Institute for Health Sciences & Technology (SAIHST); Sungkyunkwan University; Samsung Biomedical Research Institute; Seoul Korea

3. Bethel Epilepsy Center; Mara Hospital; Bielefeld Germany

4. Novartis Pharmaceuticals Corporation; East Hanover New Jersey U.S.A

5. Novartis Pharma AG; Basel Switzerland

Funder

Novartis Pharma

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/epi.13771/fullpdf

Reference13 articles.